Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 10/20 | 0.71 |
| ▸ | CHRNA4 known ✓ | P43681 | 10/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.71 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.71 |
| ▸ | CHRNG | P07510 | 2/20 | 0.71 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.71 |
| ▸ | CHRND | Q07001 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.71 |
| ▸ | HTR3A | P46098 | 1/20 | 0.71 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL29761222 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL224851 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413925 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29761223 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL22323984 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.88 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL137144 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL225687 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-4547280-A1 | BIOPOLYMER FORMULATIONS FOR DRUG DELIVERY | 11584022 Canada Inc. (CA) | 2025-05-07 | — | — | EP | claimed |
| EP-4531965-A1 | NASAL SPRAY GUIDE | Oyster Point Pharma, Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| CN-119789873-A | Biopolymer formulation for drug delivery | 11584022加拿大有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119300877-A | Nasal spray guide | 奥伊斯特普安生物制药公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2024003790-A1 | BIOPOLYMER FORMULATIONS FOR DRUG DELIVERY | 11584022 CANADA INC. (CA) | 2024-01-04 | — | — | WO | claimed |
| WO-2023235359-A1 | NASAL SPRAY GUIDE | Oyster Point Pharma, Inc. (US) | 2023-12-07 | — | — | WO | claimed |
| EP-4748444-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4531965-B1 | NASAL SPRAY GUIDE | OYSTER POINT PHARMA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4732846-A2 | HYALURONIC ACID-BASED COMPOSITIONS FOR USE IN DRY EYE TREATMENT | Nordic Group B.V. (NL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4027815-B1 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | ACHIEVE LIFE SCIENCES INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4704809-B1 | HYALURONIC ACID-BASED COMPOSITIONS FOR USE IN DRY EYE TREATMENT | NORDIC GROUP B V (NL) | 2026-04-15 | — | — | EP | disclosed |
| EP-4704838-A2 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF | Achieve Life Sciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-11318143-B2 | Treatment of alcohol use disorder | SOEDERPALM BO (SE) | 2022-05-03 | — | — | US | disclosed |
| US-20220079982-A1 | FORMULATION FOR TREATING TOBACCO OR PSYCHOTROPE WITHDRAWAL SYMPTOMS | EDELWEISS LABORATORY SA (FR) | 2022-03-17 | — | — | US | disclosed |
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20090318460-A1 | AMORPHOUS VARENICLINE TARTRATE AND PROCESS FOR THE PREPARATION THEREOF | GLENMARK (IN) | 2009-12-24 | — | — | US | disclosed |
| WO-2009065872-A2 | IMPROVED PROCESSES FOR THE SYNTHESIS OF VARENICLINE L-TARTRATE | MEDICHEM, S.A. (ES) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CHRNB2 3049/4885CHRNA4 3753/4885CHRNB4 3465/4885 |
| US-20090318460-A1 | AMORPHOUS VARENICLINE TARTRATE AND PROCESS FOR THE PREPARATION THEREOF | VCL, CHRNA7, CACNA1C | CHRNB2 58/4885CHRNA4 30/4885CHRNB4 72/4885 |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | CYP3A7, CYP3A5, COMT | CHRNB2 233/4885CHRNA4 84/4885CHRNB4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.